These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30185893)

  • 1. A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas.
    Creemers A; Ebbing EA; Pelgrim TC; Lagarde SM; van Etten-Jamaludin FS; van Berge Henegouwen MI; Hulshof MCCM; Krishnadath KK; Meijer SL; Bijlsma MF; van Oijen MGH; van Laarhoven HWM
    Sci Rep; 2018 Sep; 8(1):13281. PubMed ID: 30185893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.
    McCormick Matthews LH; Noble F; Tod J; Jaynes E; Harris S; Primrose JN; Ottensmeier C; Thomas GJ; Underwood TJ
    Br J Cancer; 2015 Jun; 113(1):107-18. PubMed ID: 26110972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.
    Chen M; Huang J; Zhu Z; Zhang J; Li K
    BMC Cancer; 2013 Nov; 13():539. PubMed ID: 24206575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of the red cell distribution width in esophageal cancer patients: A systematic review and meta-analysis.
    Xu WY; Yang XB; Wang WQ; Bai Y; Long JY; Lin JZ; Xiong JP; Zheng YC; He XD; Zhao HT; Sang XT
    World J Gastroenterol; 2018 May; 24(19):2120-2129. PubMed ID: 29785080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological and prognostic significance of epidermal growth factor receptor overexpression in patients with esophageal adenocarcinoma: a meta-analysis.
    Guo YM; Yu WW; Zhu M; Guo CY
    Dis Esophagus; 2015; 28(8):750-6. PubMed ID: 24961755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis.
    Ren JL; Wu HF; Wang WJ; Hu GM; Gu B; Zhang M; Wang YX
    Panminerva Med; 2017 Mar; 59(1):97-106. PubMed ID: 27636117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma.
    Ong CA; Shapiro J; Nason KS; Davison JM; Liu X; Ross-Innes C; O'Donovan M; Dinjens WN; Biermann K; Shannon N; Worster S; Schulz LK; Luketich JD; Wijnhoven BP; Hardwick RH; Fitzgerald RC
    J Clin Oncol; 2013 Apr; 31(12):1576-82. PubMed ID: 23509313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
    Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H
    Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of MicroRNAs in Esophageal Carcinoma: A Meta-Analysis.
    Gao S; Zhao ZY; Zhang ZY; Zhang Y; Wu R
    Clin Transl Gastroenterol; 2018 Nov; 9(11):203. PubMed ID: 30420592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis.
    Chen M; Cai E; Huang J; Yu P; Li K
    Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1126-34. PubMed ID: 22564870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis.
    Li S; Wang Z; Huang J; Cheng S; Du H; Che G; Peng Y
    BMC Cancer; 2016 Nov; 16(1):877. PubMed ID: 27835987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival.
    Loeser H; Scholz M; Fuchs H; Essakly A; Damanakis AI; Zander T; Büttner R; Schröder W; Bruns C; Quaas A; Gebauer F
    Sci Rep; 2020 Oct; 10(1):18411. PubMed ID: 33110104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
    Borg D; Larsson AH; Hedner C; Nodin B; Johnsson A; Jirström K
    J Transl Med; 2018 Oct; 16(1):290. PubMed ID: 30355278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiles of autophagy-related genes in esophageal adenocarcinoma.
    Zhu L; Dong L; Feng M; Yang F; Jiang W; Huang Z; Liu F; Wang L; Wang G; Li Q
    BMC Cancer; 2020 Oct; 20(1):943. PubMed ID: 32998713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-Reactive Protein and C-Reactive Protein-Based Scores to Predict Survival in Esophageal and Junctional Adenocarcinoma: Systematic Review and Meta-Analysis.
    Lorton CM; Higgins L; O'Donoghue N; Donohoe C; O'Connell J; Mockler D; Reynolds JV; Walsh D; Lysaght J
    Ann Surg Oncol; 2022 Mar; 29(3):1853-1865. PubMed ID: 34773194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer.
    Winther M; Alsner J; Tramm T; Baeksgaard L; Holtved E; Nordsmark M
    Acta Oncol; 2015; 54(9):1582-91. PubMed ID: 26481465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MUC2 expression is an adverse prognostic factor in superficial gastroesophageal adenocarcinomas.
    Davison JM; Ellis ST; Foxwell TJ; Luketich JD; Gibson MK; Kuan SF; Nason KS
    Hum Pathol; 2014 Mar; 45(3):540-8. PubMed ID: 24290360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma.
    Prins MJ; Verhage RJ; ten Kate FJ; van Hillegersberg R
    J Gastrointest Surg; 2012 May; 16(5):956-66. PubMed ID: 22258871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of programmed death ligand-1 immunohistochemical expression in esophageal cancer: A meta-analysis of the literature.
    Yu W; Guo Y
    Medicine (Baltimore); 2018 Jul; 97(30):e11614. PubMed ID: 30045299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation.
    Humphries MP; Craig SG; Kacprzyk R; Fisher NC; Bingham V; McQuaid S; Murray GI; McManus D; Turkington RC; James J; Salto-Tellez M
    BMC Cancer; 2020 Jun; 20(1):500. PubMed ID: 32487090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.